# US 2019/0290578 A1 · Stable oral solutions for combined api

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0290578 A1
- Document ID: US20190290578A1
- Status: Published application
- Kind: A1
- Application number: 16/374,375
- Filed: 2019-04-03
- Published: 2019-09-26
- Earliest claimed: 2013-06-05
- Assignees: Pharnext
- Applicants: Pharnext
- Inventors: Daniel Cohen; Ilya Chumakov; Serguei Nabirochkin; Viviane Bertrand
- Web page: https://patentgrep.com/patent/US20190290578A1

## CPC

- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/0095: {Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches (A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 31/047: having two or more hydroxy groups, e.g. sorbitol
- A61K 31/195: having an amino group
- A61K 31/197: the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid (carnitine A61K31/205)
- A61K 31/485: Morphinan derivatives, e.g. morphine, codeine
- A61K 47/08: containing oxygen, {e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides}
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/32: Alcohol-abuse
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a homogeneous, stable, and palatable pharmaceutical solution comprising baclofen, sorbitol and naltrexone.

## Claims

### Claim at position 1

1-16. (canceled)

### Claim 17

A pharmaceutical composition comprising, in the form of a solution:
baclofen or a pharmaceutically acceptable salt thereof, sorbitol or a pharmaceutically acceptable salt thereof, and naltrexone or a pharmaceutically acceptable salt thereof as active ingredients, and
an acetate or citrate buffer, or a combination thereof;
wherein the solution has a pH of between about 4 and about 7.

### Claim 18 (depends on 17)

The composition of claim 17, comprising naltrexone or a pharmaceutically acceptable salt thereof in an amount between about 1 and about 200 μg/mL.

### Claim 19 (depends on 18)

The composition of claim 18, comprising naltrexone or a pharmaceutically acceptable salt thereof in an amount between about 10 and about 100 μg/mL.

### Claim 20 (depends on 18)

The composition of claim 18, wherein naltrexone or a pharmaceutically acceptable salt thereof is in an amount of about 70 μg/mL.

### Claim 21 (depends on 18)

The composition of claim 18, comprising naltrexone or a pharmaceutically acceptable salt thereof in an amount of about 140 μg/mL.

### Claim 22 (depends on 17)

The composition of claim 17, wherein baclofen or a pharmaceutically acceptable salt thereof, sorbitol or a pharmaceutically acceptable salt thereof, and naltrexone or a pharmaceutically acceptable salt thereof are present in a relative weight ratio of about 8.6/300/1.

### Claim 23 (depends on 17)

The composition of claim 17, comprising:
sorbitol, or a pharmaceutically acceptable salt thereof, in an amount of about 4.2 mg/mL,
naltrexone, or a pharmaceutically acceptable salt thereof, in an amount of about 0.014 mg/mL, and
baclofen, or a pharmaceutically acceptable salt thereof, in an amount of about 0.12 mg/mL.

### Claim 24 (depends on 17)

The composition of claim 17, comprising:
sorbitol, or a pharmaceutically acceptable salt thereof, in an amount of about 21 mg/mL,
naltrexone, or a pharmaceutically acceptable salt thereof, in an amount of about 0.07 mg/mL, and
baclofen, or a pharmaceutically acceptable salt thereof, in an amount of about 0.6 mg/mL.

### Claim 25 (depends on 17)

The composition of claim 17, comprising:
sorbitol, or a pharmaceutically acceptable salt thereof, in an amount of about 42 mg/mL,
naltrexone, or a pharmaceutically acceptable salt thereof, in an amount of about 0.14 mg/mL, and
baclofen, or a pharmaceutically acceptable salt thereof, in an amount of about 1.2 mg/mL.

### Claim 26 (depends on 17)

The composition of claim 17, further comprising at least one flavoring agent.

### Claim 27 (depends on 26)

The composition of claim 26, wherein the at least one flavoring agent is isoamyl acetate.

### Claim 28 (depends on 27)

The composition of claim 27, comprising isoamyl acetate in an amount between about 0.1 and about 2.0 mg/mL.

### Claim 29 (depends on 28)

The composition of claim 28, comprising isoamyl acetate in an amount of about 0.4 mg/mL.

### Claim 30 (depends on 17)

The composition of claim 17, further comprising at least one preservative.

### Claim 31 (depends on 30)

The composition of claim 30, wherein the at least one preservative is a paraben.

### Claim 32 (depends on 31)

The composition of claim 31, wherein the at least one preservative is methyl paraben, propyl paraben, or a combination thereof.

### Claim 33 (depends on 32)

The composition of claim 32, comprising methyl paraben in a concentration of about 0.18 g per 100 mL or propyl paraben in a concentration of about 0.02 g per 100 mL of the composition, respectively; or a combination thereof.

### Claim 34

A pharmaceutical composition comprising, in the form of a solution:
sorbitol, or a pharmaceutically acceptable salt thereof, in an amount of about 4.2 mg/mL,
naltrexone, or a pharmaceutically acceptable salt thereof, in an amount of about 0.014 mg/mL,
baclofen, or a pharmaceutically acceptable salt thereof, in an amount of about 0.12 mg/mL,
isoamyl acetate in an amount of about 0.4 mg/mL,
sodium methyl paraben in an amount of about 0.18 mg/mL,
sodium propyl paraben in an amount of about 0.02 mg/mL, and
an acetate buffer;
wherein the solution has a pH of between 4 and 7.

### Claim 35 (depends on 34)

The composition of claim 34, wherein the pH of the solution is about 5.5.

### Claim 36 (depends on 34)

The composition of claim 34, wherein the acetate buffer comprises:
sodium acetate in an amount of about 2.221 g per 100 g of the final composition;
acetic acid in an amount of about 0.241 g per 100 g of the final composition; and
water in an amount of about 93.070 g per 100 g of the final composition.

### Claim 37 (depends on 17)

The composition of claim 17, wherein the composition is free of paraben.

### Claim 38 (depends on 17)

The composition of claim 17, comprising at least one further compound selected from the group consisting of antioxidants, emulsifiers, viscosity modifiers, sweeteners, flavor enhancers, coloring agents, co-solvents, solubilizers, and combinations thereof.

### Claim 39 (depends on 17)

The composition of claim 17, wherein the sorbitol or a pharmaceutically acceptable salt thereof is D-sorbitol, the baclofen or a pharmaceutically acceptable salt thereof is RS baclofen, and the naltrexone or a pharmaceutically acceptable salt thereof is naltrexone HCl.

### Claim 40 (depends on 23)

The composition of claim 23, wherein the sorbitol or a pharmaceutically acceptable salt thereof is D-sorbitol, the baclofen or a pharmaceutically acceptable salt thereof is RS baclofen, and the naltrexone or a pharmaceutically acceptable salt thereof is naltrexone HCl.

### Claim 41 (depends on 24)

The composition of claim 24, wherein the sorbitol or a pharmaceutically acceptable salt thereof is D-sorbitol, the baclofen or a pharmaceutically acceptable salt thereof is RS baclofen, and the naltrexone or a pharmaceutically acceptable salt thereof is naltrexone HCl.

### Claim 42 (depends on 25)

The composition of claim 25, wherein the sorbitol or a pharmaceutically acceptable salt thereof is D-sorbitol, the baclofen or a pharmaceutically acceptable salt thereof is RS baclofen, and the naltrexone or a pharmaceutically acceptable salt thereof is naltrexone HCl.

### Claim 43 (depends on 17)

A method for preparing the composition of claim 17, comprising the steps of providing baclofen or a pharmaceutically acceptable salt thereof, sorbitol or a pharmaceutically acceptable salt thereof, and naltrexone or a pharmaceutically acceptable salt thereof; and admixing said baclofen or a pharmaceutically acceptable salt thereof, sorbitol or a pharmaceutically acceptable salt thereof, and naltrexone or a pharmaceutically acceptable salt thereof in a citrate or acetate buffer, wherein the resulting solution has a pH between 4 and 7.

### Claim 44 (depends on 43)

The method of claim 43, comprising the steps of:
i) preparing a first solution by:
dispensing about 20% of a desired final volume of an acetate buffer;
then dissolving sodium methyl paraben and sodium propyl paraben;
then heating to 45-55° C., optionally with stirring, until dissolved;
then cooling to about 25-35° C.;
ii) preparing a second solution by:
dispensing about 70% of the desired final volume of acetate buffer;
then adding sorbitol, naltrexone, and baclofen;
then mixing until dissolved;
iii) mixing the first and second solutions obtained in step i) and ii);
iv) optionally, adding a flavoring agent to the solution obtained in step iii) and mixing until dissolved;
v) if needed, adjusting pH to 5.4-5.6 with 50% w/w NaOH solution or acetic acid; and
vi) if needed, adding sufficient acetate buffer to reach the desired final volume.

### Claim 45 (depends on 43)

The method of claim 43, comprising the steps of:
i) dispensing about 90% of an amount of water required for a total batch size;
ii) optionally adding sodium methyl paraben and sodium propyl paraben, then mixing until dissolved;
iii) adding sodium acetate and acetic acid, then mixing until dissolved;
iv) adding sorbitol, naltrexone and baclofen;
v) adding isoamyl acetate, then mixing until dissolved;
vi) if needed, adjusting pH to 5.4-5.6 with a 50% w/w NaOH solution or acetic acid; and
vii) if needed, adding sufficient water to provide a total weight consistent with the total batch size.

### Claim 46 (depends on 17)

A method of treating Charcot-Marie-Tooth disease of type 1A (CMT1A), comprising administering the composition of claim 17 to a human subject in need thereof.

### Claim 47 (depends on 17)

A container comprising the composition of claim 17.

### Claim 48 (depends on 17)

A container comprising the composition of claim 17 in a volume of 100 mL.

### Claim 49 (depends on 17)

A patient pack comprising a set of single-dose sachets or ampoules containing the composition of claim 17 in a suitable amount for treating CMT1A in a human subject in need thereof.

### Claim 50 (depends on 17)

A pharmaceutical kit of parts comprising a bottle comprising the composition of claim 17; a cap or a pipette or a pipette-cap system; and optionally instructions for administration of the composition.

### Claim 51 (depends on 17)

A pharmaceutical kit of parts that allows preparation of the composition of claim 17, and optionally instructions for preparing the composition.
